These excerpts taken from the SNTA 10-K filed Mar 26, 2009.
WHEREAS, ROCHE has expertise and capability in the research, development, manufacture and commercialization of pharmaceutical products;
WHEREAS, SYNTA is a biopharmaceutical company focused on discovering, developing and commercializing products for extending and enhancing the lives of patients with severe medical conditions, including inflammatory and immune-mediated diseases and disorders; and
WHEREAS, SYNTA and ROCHE desire to collaborate on the discovery, research, development and commercialization of certain potential products containing small-molecule compounds that may be contributed to the collaboration by either party and directed to the inhibition of calcium release-activated calcium channels.
NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration the receipt of which is hereby acknowledged, SYNTA and ROCHE agree as follows:
WHEREAS, ROCHE has expertise
WHEREAS, SYNTA is a
WHEREAS, SYNTA and ROCHE desire
NOW, THEREFORE, in